Drug Profile
Ketoprofen/nifedipine
Alternative Names: OMS-201Latest Information Update: 10 May 2017
Price :
$50
*
At a glance
- Originator Omeros Corporation
- Class Antispasmodics; Dihydropyridines; Muscle relaxants; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
- Mechanism of Action Calcium channel antagonists; Lipoxygenase-cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Inflammation; Pain; Spasm
Most Recent Events
- 16 Mar 2017 Omeros Corporation has patent protection for for ketoprofen/nifedipine for pain, inflammation and spasm in USA and ex-US countries
- 04 May 2012 Omeros plans a phase II programme for Inflammation, Pain and Spasm
- 30 Dec 2010 Final adverse events data from a Phase-I/II trial in Inflammation, Pain and Spasm released by Omeros